Dalbavancin Market Size, Share & Trends Analysis Report By Product (Intravenous Therapy, Oral Type), By Applications (Skin Infection, Soft Tissue Infection, Others), By End Use, By Region, and Segment Forecasts - 2035

DALBAVANCIN MARKET REPORT OVERVIEW

The global dalbavancin market size was valued at USD 699.1 million in 2025 and is projected to grow from USD 746.77 million in 2026 to USD 1352.76 million by 2035, at a CAGR of 6.82% from 2026 to 2035.

It provide the user with a lot of features that make this particular product service work efficiently and effectively. One second-generation lipoglycopeptide antibiotic is dalapavancin, which is marketed under several names including Xydalba in the EU and Dalvance in the US. This factor has augmented the Dalbavancin Market growth.

The Anticipated rate of growth for this particular product service is due to quality level of assurance. Prosperity has been observed for this particular product market with amusing numbers. The primary drivers driving the market's expansion include increased rates of multiple sclerosis, cerebral palsy, and encephalitis in all regions when compared to prior years. Additionally, it was shown that cerebral palsy (CP) is the primary cause of spasticity, impacting over 80% of those who have the illness. As a result, the desire for an effective therapy is fueling the expansion of the global market for spasticity medications. This has ultimately outraged the sales and demand for this particular market growth and prosperity.

• • 

    Download Free sample to learn more about this report.

DALBAVANCIN MARKET KEY FINDINGS

• Market Size and Growth: The Dalbavancin Market size was USD 550 million in 2024, is projected to grow to USD 600 million by 2025, and exceed USD 1,200 million by 2033, with a CAGR of 9.5% from 2025 to 2033.

• Key Market Driver: Rising bacterial resistance is pushing doctors to think outside the usual antibiotic playbook. MRSA alone affects over 120,000 people annually in the U.S., and dalbavancin’s once-weekly dose makes it a go-to for serious skin infections.

• Major Market Restraint: The cost is steep—treatment courses can range between $3,000 to $4,500, which puts it out of reach for some patients and limits adoption in resource-constrained hospitals.

• Emerging Trends: Outpatient and home infusion use is rising. Hospitals using dalbavancin report 30% fewer overnight admissions, thanks to shorter IV therapy durations and fewer complications.

• Regional Leadership: North America remains the leader, contributing to over 50% of the global demand, driven by higher infection rates, insurance coverage, and faster regulatory nods.

• Competitive Landscape: Fewer than 10 global pharma companies currently operate in this space, with AbbVie (via Allergan) leading in branded production. It’s a tight race, with few substitutes on the market.

• Market Segmentation: Injectable formulations account for more than 90% of total usage, as oral alternatives haven’t passed regulatory review yet and the IV route remains the standard for serious cases.

• Recent Development: In 2024, several U.S. hospital networks added dalbavancin to their outpatient protocols, reporting a 20% drop in hospital readmissions for acute bacterial skin infections.

COVID-19 IMPACT: MARKET GROWTH OBSTRUCTED BY PANDEMIC DUE TO LOCKDOWN

The Global COVID-19 pandemic has been unprecedented and staggering, with the market experiencing higher-than-anticipated demand across all regions compared to pre-pandemic levels. The sudden market growth reflected by the rise in CAGR is attributable to market’s growth and demand returning to pre-pandemic levels.

This has affected the overall supply and demand chains of the particular market. As a result of the government's lockdown and other steps to stop the coronavirus from spreading, all supply activities were postponed, which decreased the amount of product related to healthcare. Therefore, a small influence from COVID-19 is anticipated on the Dalbavancin Market share.

LATEST TRENDS

"Spasticity Medications to Drive Market Growth"

A latest trend has been witnessed to proliferate the market growth. In terms of spasticity medication sales, the oral route segment is anticipated to hold the biggest share. Because of how simple it is to administer these drugs, which aid patients when their daily muscle function is being affected by spasticity, the reason for their dominance can be traced to their greater use. Drug administration does not require the expertise of a highly qualified healthcare provider.  A lot of specifications have been made to this particular product which has benefited the market growth. This specific trend has influenced the market growth so much so that the revenue and share numbers of this particular product is touching the skies and soaring over.

• • 

    Download Free sample to learn more about this report.

DALBAVANCIN MARKET SEGMENTATION

By Type

Based on type the global market can be categorized into Intravenous Therapy and Oral Type amongst which the leading segment is the Intravenous Therapy.

• Intravenous Therapy: It is nothing but a type of dalbavancin with the Intravenous Therapy.

• Oral Type: It is basically a type that of dalbavancin with the Oral Type.

By Application

Based on application the global market can be categorized into Skin Infection, Soft Tissue Infection, and Others amongst which the leading segment is the Skin Infection.

• Skin Infection: It is just an application where it is used by Skin Infection.

• Soft Tissue Infection: It is nothing but an application where it is used by Soft Tissue Infection.

DRIVING FACTORS

"Biopharmaceuticals to Boost the Market"

This is the major factor attributing the growth of this particular market. In today's cyber environment, law firms are among the businesses struggling to remain competitive. The market is expanding as a result of growing awareness and prevalence of acute bacterial skin and skin structure infections as well as enhanced research and development (R&D) efforts by pharmaceutical and biopharmaceutical companies to provide innovative therapies and new products. This particular factor has been proved to a boon for this particular product market. These factors are anticipated to drive the market growth during the forecast period.

"Merger & Aquisitions to Expand the Market"

This is the second major factor attributing the growth of this particular  market and has resulted in the hike of revenue numbers so much so that they are touching the skies. Clients benefit from it. Drug approvals, increasing R&D spending by pharmaceutical and biotechnology companies, and expanding pipeline development activity are expected to propel the market during the projected period. Growing product launches and a range of actions by major competitors in the market, including partnerships, collaborations, and mergers & acquisitions, are expected to propel the market. This factor has attributed the overall growth of this market and helped with the hike of revenue numbers as well. These factors are anticipated to drive the market growth in the present times and also during the forecast period.

RESTRAINING FACTOR

"High Costs and Unavailability to Impede Market Growth"

These particular solutions have been very helpful yet extremely costly as well. In the future, the market is anticipated to be hampered by strict government regulations and patent expiration. This particular factor is anticipated to restrain the market growth and drastically reduce the sales and demands of this particular product market.

• • 

    Download Free sampleto learn more about this report.

•  

DALBAVANCIN MARKET REGIONAL INSIGHTS

The Market is primarily segmented into Europe, Latin America, Asia Pacific, North America, and Middle East & Africa.

"North America Dominating the Market due to Advanced Technology"

North America is expected to be the leading region of this particular product market and is anticipated to to grow over the forecasted period. Because more people are experiencing cervical dystonia, muscle atrophy, and different traumatic brain injuries that result in spasticity, North America is predicted to lead the market for spasticity medications. Public health awareness is growing, and government campaigns to raise awareness are probably going to open up more business options. The expansion of the spasticity medicine market in the region is expected to be driven by an increase in disposable income over the proposed forecast period.

KEY INDUSTRY PLAYERS

"Leading Players adopt Acquisition Strategies to Stay Competitive"

Several players in the market are using acquisition strategies to build their business portfolio and strengthen their market position. In addition, partnerships and collaborations are among the common strategies adopted by companies. Key market players are making R&D investments to bring advanced technologies and solutions to the market.

List of Market Players Profiled

• Roche (Switzerland)
• Pfizer (U.S.)
• Abbvie (U.S.)
• Johnson (U.S.)
• Sanofi (France)

INDUSTRIAL DEVELOPMENT

February 2032: This particular company has attributed the market growth in terms of revenue and shares system. The FDA in the United States has granted approval for XEOMIN, or incobotulinum toxin A, a supplemental biologics license application. This development has proved that the company will continue to proliferate this particular product market growth.

REPORT COVERAGE

This Research profiles a report with extensive studies that take into description the firms that exist in the market affecting the forecasting period. With detailed studies done, it also offers a comprehensive analysis by inspecting the factors like segmentation, opportunities, industrial developments, trends, growth, size, share, and restraints. This analysis is subject to alteration if the key players and probable analysis of market dynamics change.